Please assess the completion status of the following clinical trial:

Trial Title: Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-65 years old~* Male or female~* Diagnosed with GAD according to DSM-IV~* HAMA score≥17~* Provide with written informed consent~* Agree to be washed-out for two weeks if receiving SSRI, SNRI or NASA.~Exclusion Criteria:~* Serious suicidal tendency~* The score of the sixth item of HAMA ≥3~* The score of HAMD ≥21~* Pregnant or lactating women~* History of allergic or hypersensitivity to tandospirone~* Serious or unstable cardiac, renal, neurologic, cerebrovascular, metabolic, or pulmonary disease~* Secondary anxiety disorders~* Drug or alcohol dependence within 1 year~* Patients currently taking benzodiazepine drugs~* Drivers and dangerous machine operators~* Participated in other clinical studies in the last 30 days~* Patients with clinically significant ECG or laboratory abnormalities~* Patients with a history of epilepsy~* Patients with abnormal TSH concentration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Control Group (Type: ACTIVE_COMPARATOR): Patient randomized to control group is administrated with usual dose of tandospirone treatment, 30 mg/day
- Study Group (Type: EXPERIMENTAL): Comparative high dose of tandospirone treatment, 60 mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).